Decreased neurokinin-1 (substance P) receptor binding in patients with panic disorder: positron emission tomographic study with [18F]SPA-RQ. - Wikidata - wikimedia - TriplyDB

Decreased neurokinin-1 (substance P) receptor binding in patients with panic disorder: positron emission tomographic study with [18F]SPA-RQ.

Decreased neurokinin-1 (substance P) receptor binding in patients with panic disorder: positron emission tomographic study with [18F]SPA-RQ.

http://www.wikidata.org/entity/Q37461957

about

Anxiolytic-like effects of the neurokinin 1 receptor antagonist GR-205171 in the elevated plus maze and contextual fear-potentiated startle model of anxiety in gerbils.Biological markers for anxiety disorders, OCD and PTSD - a consensus statement. Part I: Neuroimaging and genetics.A selective neurokinin-1 receptor antagonist in chronic PTSD: a randomized, double-blind, placebo-controlled, proof-of-concept trial.Revise the revised? New dimensions of the neuroanatomical hypothesis of panic disorder.Diminished neurokinin-1 receptor availability in patients with two forms of chronic visceral pain Corticotropin releasing hormone and imaging, rethinking the stress axis.Heart rate and respiratory response to doxapram in patients with panic disorder.Increased neurokinin-1 receptor availability in the amygdala in social anxiety disorder: a positron emission tomography study with [11C]GR205171.Biological markers for anxiety disorders, OCD and PTSD: A consensus statement. Part II: Neurochemistry, neurophysiology and neurocognition.Emerging drugs for panic disorder.Novel investigational therapeutics for panic disorder.Overlapping expression of serotonin transporters and neurokinin-1 receptors in posttraumatic stress disorder: a multi-tracer PET study.Gender differences in brain serotonin transporter availability in panic disorder.

P2860

Q30479172-D7DA3476-DCFE-473C-B1DA-E36591B5A32E Q31114020-98EB7AFA-648C-49F8-B9B6-A78D49EEEA60 Q34157073-D1F59385-63A3-45E2-B884-20BBDC0E2F7E Q34301905-48D0E309-A7D1-4F34-BA35-B0632B925CFE Q34954885-74F2CAFF-47DE-4A99-8B4F-5E6E6CEB261D Q35181618-B7D5BD80-EB77-4638-AC0A-9CC9847069EF Q35572089-10C688F5-6096-417E-90DD-42C10C3FE50C Q37347599-58A43EB1-E534-4EC0-A290-7BABAB9CAE03 Q37686937-9CFD4637-2CD1-406C-B4B5-DB928460A2DD Q37945699-30C04DD9-A2AB-4B9F-9CA8-0D64438830A3 Q38300166-2DB9F062-4800-4F77-9BD2-6AC9AE6DE5B3 Q48096370-0C7A0A27-2C86-43BB-BF29-8BA9D3B66C8E Q51528935-3D4D1805-668E-41B3-86E7-B0EFC063C460

P2860

Decreased neurokinin-1 (substance P) receptor binding in patients with panic disorder: positron emission tomographic study with [18F]SPA-RQ.

http://www.wikidata.org/entity/Q37461957

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 07 February 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Decreased neurokinin-1 (substa ...... raphic study with [18F]SPA-RQ.

@en

Decreased neurokinin-1

@nl

type

label

Decreased neurokinin-1 (substa ...... raphic study with [18F]SPA-RQ.

@en

Decreased neurokinin-1

@nl

prefLabel

Decreased neurokinin-1 (substa ...... raphic study with [18F]SPA-RQ.

@en

Decreased neurokinin-1

@nl

P1433

Q37461957-CDF8FC1A-0FC3-4A54-A7BB-EFF0A9084F4D

P1476

Q37461957-4DE9B0C6-CA10-440D-A74C-2F77AFBDEC8E

P2093

Q37461957-0C44972A-FB20-46F3-A606-40D55987E3D1

Q37461957-18CAC882-87CC-4107-84C8-294EB68FFFCB

Q37461957-4CE25A33-380E-4E2D-9B70-9DF15C50A4D8

Q37461957-821520C4-B4C0-4DFC-9E25-592599084012

Q37461957-97E453A5-D060-4864-BE21-396F394F43E4

Q37461957-9EBBC7C1-876E-4155-A0BC-585016B0B1AD

Q37461957-A9097B91-BDE0-4689-8205-A7BA428F873C

Q37461957-C0F93AE9-39CE-4ED0-9D43-AE7EF43252BE

Q37461957-C4F400E0-9B5E-4D86-BFDC-7D392399ECD9

Q37461957-D26CEFD6-D00B-4791-A28E-8A284677EE8C

P2860

Q37461957-078D527F-7A9A-47AC-84DD-F60543D37C41

Q37461957-144CED67-40AC-4199-90E4-36A582224A69

Q37461957-4178295D-7211-46D0-8AA2-43661C0E4D1D

Q37461957-49CC1EF3-4C44-4D55-AD7F-384915140076

Q37461957-4BA86219-BF3E-470D-A790-3404737BD585

Q37461957-51400D3B-229F-475A-8657-73C52158D76B

Q37461957-65C37129-EAAF-4CA6-B41C-39CC2C85B523

Q37461957-7480E98A-3B9E-44AF-82D0-14C290BBABEA

Q37461957-81F49C8D-2A35-4CC2-B837-9F8DCB3E8C82

Q37461957-91B542E2-85AA-46DD-BAED-A7F618A9F5AF

P304

Q37461957-07E96436-370C-44F7-B7B7-E39E6422EEAD

P31

Q37461957-97C5E239-A7AD-4991-A68B-EF5326E6A2E5

P356

Q37461957-5DB84BF5-F85E-43C5-BB81-AC99F833D888

P407

Q37461957-6D47F2A8-19F2-4269-984B-E358D6DF51C8

P433

Q37461957-6A7220B1-438D-4DC3-90C0-DDFED0D54DF7

P478

Q37461957-3CAAE3DF-2076-4F9A-AE1C-F2965D1CFEFC

P577

Q37461957-52656E04-A629-4725-8DD8-1490CC49A416

P5875

Q37461957-0ED082A2-5F95-4B30-9152-78F9D3D90977

P698

Q37461957-A7719563-4A7A-4D58-9C88-038B3E8FEDF4

P921

Q37461957-40F67F86-3D72-4A4C-84D2-4F9A4127FB9F

P932

Q37461957-984E86B3-EFD9-40B6-89C3-963F8CD3C3CD

P356

J.BIOPSYCH.2008.12.027

P1433

Biological Psychiatry

P1476

Decreased neurokinin-1 (substa ...... raphic study with [18F]SPA-RQ.

@en

P2093

Alicja Lerner

http://www.w3.org/2001/XMLSchema#string

Amanda Farris

http://www.w3.org/2001/XMLSchema#string

Cheryl Morse

http://www.w3.org/2001/XMLSchema#string

Daniel S Pine

http://www.w3.org/2001/XMLSchema#string

Fumihiko Yasuno

http://www.w3.org/2001/XMLSchema#string

H Donald Burns

http://www.w3.org/2001/XMLSchema#string

Jeih-San Liow

http://www.w3.org/2001/XMLSchema#string

Marilla Geraci

http://www.w3.org/2001/XMLSchema#string

Richard Hargreaves

http://www.w3.org/2001/XMLSchema#string

Robert B Innis

http://www.w3.org/2001/XMLSchema#string

P2860

Distinct mechanism for antidepressant activity by blockade of central substance P receptors

An inventory for measuring clinical anxiety: psychometric properties

PET imaging of neurokinin-1 receptors with [(18)F]SPA-RQ in human subjects: assessment of reference tissue models and their test-retest reproducibility.

Reliability and validity of the Panic Disorder Severity Scale: replication and extension.

Linearized reference tissue parametric imaging methods: application to [11C]DASB positron emission tomography studies of the serotonin transporter in human brain.

Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo.

Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder.

Elevated cerebrospinal fluid substance p concentrations in posttraumatic stress disorder and major depression.

Consensus nomenclature for in vivo imaging of reversibly binding radioligands.

Neuroendocrine pharmacology of stress.

P304

94-97

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.BIOPSYCH.2008.12.027

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

66

http://www.w3.org/2001/XMLSchema#string

P577

2009-02-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23988398

http://www.w3.org/2001/XMLSchema#string

P698

19200949

http://www.w3.org/2001/XMLSchema#string

P921

P932

2789441

http://www.w3.org/2001/XMLSchema#string